<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00729287</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000602239</org_study_id>
    <nct_id>NCT00729287</nct_id>
  </id_info>
  <brief_title>Selenium in Preventing Cancer Recurrence in Patients With Bladder Cancer</brief_title>
  <acronym>SELEBLAT</acronym>
  <official_title>Phase III Randomized Chemoprevention Study of Selenium on the Recurrence of Non-invasive Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Katholieke Universiteit Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agentschap voor Innovatie door Wetenschap en Technologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Katholieke Universiteit Leuven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing,
      or coming back. The use of selenium may keep bladder cancer from growing or coming back. It
      is not yet known whether selenium is more effective than a placebo in preventing cancer
      recurrence in patients with bladder cancer.

      PURPOSE: This randomized phase III trial is studying selenium to see how well it works
      compared with a placebo in preventing cancer recurrence in patients with bladder cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine the effect of selenium, when administered with standard care, in preventing
           the recurrence of bladder cancer in patients with non-muscle-invasive transitional cell
           carcinoma of the bladder at risk for recurrence.

      Secondary

        -  To determine the effect of selenium on the recurrence of bladder cancer, in terms of
           histological type, number, and size.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients receive oral placebo daily in addition to standard care.

        -  Arm II: Patients receive oral selenium daily in addition to standard care.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of selenium in preventing the recurrence of bladder cancer</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of selenium on the progression of bladder cancer, in terms of histological type, number, and size</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">276</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive oral placebo daily in addition to standard care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral selenium daily in addition to standard care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>selenium</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

        Histopathologically confirmed non-muscle-invasive transitional cell carcinoma (TCC) of the
        bladder (&lt; pT2 )

        PATIENT CHARACTERISTICS:

          -  Able to swallow pills

          -  Not pregnant

          -  Fertile patients must use effective contraception

          -  No other malignancy within the past 5 years

          -  No known hypersensitivity or adverse reactions to selenium

          -  No other serious medical or psychiatric illness that would preclude giving informed
             consent

          -  No condition that, in the opinion of the investigator, may interfere with the safety
             of the patient or the evaluation of the study objectives

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  More than 30 days since prior daily dietary supplements containing selenium

          -  No other concurrent selenium (contained in individual supplements, antioxidant mix, or
             multivitamin) intake

          -  No concurrent participation in another study involving a medical, surgical,
             nutritional, or lifestyle intervention

               -  Concurrent participation in the follow-up phase of another study allowed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Buntinx, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of public Health, KU Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of public Health, KU Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2008</study_first_submitted>
  <study_first_submitted_qc>August 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2008</study_first_posted>
  <last_update_submitted>May 10, 2016</last_update_submitted>
  <last_update_submitted_qc>May 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Katholieke Universiteit Leuven</investigator_affiliation>
    <investigator_full_name>Maria Goossens</investigator_full_name>
    <investigator_title>Prof. dr. Frank Buntinx</investigator_title>
  </responsible_party>
  <keyword>stage 0 bladder cancer</keyword>
  <keyword>stage I bladder cancer</keyword>
  <keyword>transitional cell carcinoma of the bladder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Selenium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

